By Fineline Cube 
Nanjing-based Minova Pharmaceuticals Co., Ltd announced last week that it has received marketing approval from the National Medical Products Administration (NMPA) for its self – developed deoxycholic acid injection, branded as Rongzhi. This makes it the first adipocytolytic drug approved in China for treating moderate – to – severe convexity or fullness caused by submental fat accumulation, commonly known as “double chin” in adults.
Significance of the Approval
This breakthrough product addresses China’s previously unmet need for non – surgical precision fat reduction, marking a major advancement in the country’s non – invasive medical aesthetic contouring technology. Rongzhi provides Chinese patients with a safe and effective new option for localized fat management.
Industry Impact
The approval of Rongzhi establishes an important milestone in China’s aesthetic medicine sector. It represents a significant step forward in offering patients innovative, non – surgical solutions for body contouring, potentially transforming the landscape of aesthetic treatments in the country.-Fineline Info & Tech